What is Photocure ASA's (PHO.OL) StockRank?

MoatMap's StockRank for Photocure ASA (PHO.OL) is 70/100, with a Buy signal. This is a composite score combining Quality (63), Value (48), and Momentum (48) factor ranks across MoatMap's 20,000+ stock universe.

Does Photocure ASA have an economic moat?

Photocure ASA (PHO.OL) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Photocure ASA a buy, hold, or sell?

MoatMap's current signal for Photocure ASA (PHO.OL) is Buy, based on a StockRank of 70/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Photocure ASA in?

Photocure ASA (PHO.OL) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Norway).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PHO.OL

BUYREMOVE

Photocure ASA · Healthcare · Norway · $166M · Avg Vol: $366K/d

StockRank

P/E (TTM)

19.0x

ROE

16.1%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Photocure is a niche bladder cancer diagnostics company. While it has a solid product (Hexvix/Cysview), it is not a CDMO and does not benefit from the broader CDMO pricing power cycle or other core macro themes.

COMPANY DESCRIPTION

Photocure ASA is a specialty pharmaceutical company focused on bladder cancer management through its proprietary photodynamic technology, Hexvix/Cysview. The company holds a virtual monopoly in blue-light cystoscopy imaging agents, which significantly improve bladder cancer detection. Its competitive moat is secured by strong patent protection, regulatory approvals, and established clinical guidelines worldwide.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	40.6M	51.7M	54.2M	55.0M	10.6%
EPS	—	-0.27	0.00	-0.02	-0.01	—
Shares	—	27.1M	27.1M	27.1M	27.1M	0.0%
Debt	1.3M	5.0M	2.9M	2.7M	1.1M	-4.6%
Equity	—	47.8M	49.8M	51.8M	50.0M	1.5%
Op CF	—	-0.2M	5.0M	7.9M	3.3M	-19.0%
Inv CF	—	-0.2M	-61,307	0.1M	-1.0M	—
Fin CF	—	-5.3M	-5.8M	-4.5M	-8.0M	—

PRICE (1Y)-5.6%

SMA 50SMA 200

$6.24

RSI (14)

52.8

52W High

$8.24

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

1.3%46.8

ROE

16.1%84.2

GP/Assets

88.8%96.6

Op. Margin

45.6%97.5

FCF/Assets

-9.2%29.0

Piotroski

549.0

Int. Cover

0.3x37.2

D/E Ratio

—N/A

Current Ratio

4.79x69.9

Value

P/E (TTM)

19.0x59.0

EV/EBITDA

9.4x70.4

P/FCF

—N/A

P/B

2.8x47.0

P/S

2.4x62.1

Div Yield

—N/A

Momentum

52W High %

76%64.5

RS 6M

-32%35.9

SMA 50/200

1.01x64.9

EPS Rev 4W

+172.1%99.7

EPS Rev 12W

—N/A

EPS Improve

+28%38.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$166M

P/E (Forward)

14.9x

Gross Margin

93.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PHO.OL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
PHO.OL	Photocure ASA(you)	$166M	70	BUY
VISTN.OL	Vistin Pharma ASA	$93M	99	STRONG BUY
NYKD.OL	Nykode Therapeutics AS	$109M	46	HOLD
AZT.OL	ArcticZymes Technologies ASA	$107M	45	HOLD
MEDI.OL	Medistim ASA	$438M	86	STRONG BUY
TRMED.OL	Thor Medical ASA	$157M	20	SELL
CRNA.OL	Circio Holding ASA	$232M	20	SELL
ZLNA.OL	Zelluna ASA	$51M	20	SELL

Peer medians: ROE -4.7% · P/E 26.9x · Gross margin 88.0%

Photocure ASA (PHO.OL) — Stock Score Summary

Photocure ASA (PHO.OL) has a MoatMap StockRank of 70/100 based on Quality (63/100), Value (48/100), and Momentum (48/100) factor scores. The current signal is BUY. Photocure is a niche bladder cancer diagnostics company. While it has a solid product (Hexvix/Cysview), it is not a CDMO and does not benefit from the broader CDMO pricing power cycle or other core macro themes.

Key Financial Metrics

Price	$6.24
Market Cap	$166M
P/E (TTM)	19.05
P/E (Forward)	14.93
Price/Book	2.76
Return on Equity	16.1%
Return on Invested Capital	1.3%
Gross Margin	93.6%
Operating Margin	45.6%
Revenue Growth	111.1%
Free Cash Flow	$-724K

Photocure ASA operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Norway).

Frequently Asked Questions

What is Photocure ASA’s (PHO.OL) StockRank?: MoatMap’s StockRank for Photocure ASA (PHO.OL) is 70/100, with a Buy signal. It is a composite of Quality (63), Value (48), and Momentum (48) factor ranks across MoatMap’s 20,000+ stock universe.
Does Photocure ASA have an economic moat?: Photocure ASA (PHO.OL) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Photocure ASA a buy, hold, or sell?: MoatMap’s current signal for Photocure ASA (PHO.OL) is Buy, based on a StockRank of 70/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Photocure ASA in?: Photocure ASA (PHO.OL) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Norway).